Inhibice RANK-ligandu v boji proti sarkopenii se základní osteoporózou
Inhibice ligandu RANK v boji proti sarkopenii se základní osteoporózou: Randomizovaná, dvojitě zaslepená, dvojitě falešná, aktivně kontrolovaná studie
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Aims:
- To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
- To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Ronald Man Yeung Wong
- Telefonní číslo: 852 3505 1654
- E-mail: ronald.wong@cuhk.edu.hk
Studijní místa
-
-
-
Hong Kong, Čína
- Nábor
- The Chinese University of Hong Kong
-
Kontakt:
- Ronald Man Yeung Wong
- Telefonní číslo: 852 3505 1654
- E-mail: ronald.wong@cuhk.edu.hk
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Elderly males or females aged 65 years or older
- diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
- Willing and able to comply with study protocol including follow-up evaluations.
Exclusion Criteria:
- history of recent fracture i.e., within 3 months
- history of prior anti-osteoporotic drug
- disease or medication affecting bone or muscle metabolism
- Chairbound or bedbound
- Unable to agree for consent
- contraindication to drug i.e., Denosumab or Zoledronic Acid
- Underlying malignancy or disease known to cause cachexia
- severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
- moderate to severe liver failure (Child-Pugh Class B or C).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: Denosumab group
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
|
Komparátor placeba: Zolendronic acid group
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
6-metre walk
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as &lt;1.0m/s. |
From enrollment to the end of treatment at 52 weeks
|
|
5-time chair stand test
Časové okno: From enrollment to the end of treatment at 8 weeks
|
The time to rise from a chair 5 times is recorded. The cut-off for is taken at &gt;=12 seconds. |
From enrollment to the end of treatment at 8 weeks
|
|
Appendicular skeletal muscle mass (ASM)
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is &lt; 7 kg/m2 for men and 5.4 kg/m2 for women. |
From enrollment to the end of treatment at 52 weeks
|
|
Handgrip strength
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is &lt; 28kg, and female is &lt;18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction |
From enrollment to the end of treatment at 52 weeks
|
|
Quadriceps muscle strength
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%). |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s) |
From enrollment to the end of treatment at 52 weeks
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Falls
Časové okno: From enrollment to the end of treatment at 52 weeks
|
To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year |
From enrollment to the end of treatment at 52 weeks
|
|
Fracture
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Assess occurrence of a fracture within a year of study period. |
From enrollment to the end of treatment at 52 weeks
|
|
Quality of life Short Form-36 (SF-36)
Časové okno: From enrollment to the end of treatment at 52 weeks
|
The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life. |
From enrollment to the end of treatment at 52 weeks
|
|
Physical activity scale for elderly (PASE)
Časové okno: From enrollment to the end of treatment at 52 weeks
|
It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity |
From enrollment to the end of treatment at 52 weeks
|
|
Food frequency questionnaire
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong. |
From enrollment to the end of treatment at 52 weeks
|
|
Hospital admissions
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Number and cause of emergency hospital admission within 1 year of study period are documented. |
From enrollment to the end of treatment at 52 weeks
|
|
Mortality
Časové okno: From enrollment to the end of treatment at 52 weeks
|
Mortality within 1-year of study period is documented. |
From enrollment to the end of treatment at 52 weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 2022.555
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .